Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia.
Cilloni D, Carturan S, Bracco E, Campia V, Rosso V, Torti D, Calabrese C, Gaidano V, Niparuck P, Favole A, Signorino E, Iacobucci I, Morano A, De Luca L, Musto P, Frassoni F, Saglio G.
Cilloni D, et al. Among authors: frassoni f.
Leuk Res. 2013 May;37(5):520-30. doi: 10.1016/j.leukres.2013.01.014. Epub 2013 Feb 12.
Leuk Res. 2013.
PMID: 23415111
Clinical Trial.